Entrada Therapeutics (TRDA) Treasury Shares (2020 - 2026)

Entrada Therapeutics' Treasury Shares history runs 6 years deep, the most recent figure standing at $2.8 million for Q1 2026.

• In Q1 2026, Treasury Shares rose 3.35% year-over-year to $2.8 million; the TTM figure through Mar 2026 stood at $2.8 million (up 3.35% YoY), while the FY2025 annual figure was $2.3 million, up 16.05% from the prior year.
• Treasury Shares was $2.8 million for Q1 2026 at Entrada Therapeutics, up from $2.3 million in the prior quarter.
• In the past five years, Treasury Shares ranged from a high of $2.8 million in Q1 2026 to a low of $295104.0 in Q2 2022.
• Historically, Treasury Shares has averaged $1.3 million across 5 years, with a median of $1.2 million in 2023.
• Biggest YoY gain for Treasury Shares was 437.67% in 2025; the steepest drop was 78.21% in 2025.
• A 5-year view of Treasury Shares shows it stood at $463964.0 in 2022, then surged by 173.4% to $1.3 million in 2023, then soared by 55.18% to $2.0 million in 2024, then advanced by 16.05% to $2.3 million in 2025, then advanced by 22.01% to $2.8 million in 2026.
• The last three Treasury Shares figures came in at $2.8 million (Q1 2026), $2.3 million (Q4 2025), and $2.4 million (Q3 2025), per Business Quant data.